Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.68 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | PGR | P06401 | 3/20 | 0.68 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | SHBG | P04278 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21973842 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL19665917 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL2903882 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL2903879 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL14523062 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL19665918 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL15904751 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL17361272 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL15920488 | 0.89 | HIF1A (0.67) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL18878439 | 0.88 | HIF1A (0.71) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3795578-A2 | HYDROXYSTEROID COMPOUNDS, THEIR INTERMEDIATES, PROCESS OF PREPARATION, COMPOSITION AND USES THEREOF | Sphaera Pharma Pvt. Ltd. (IN) | 2021-03-24 | — | — | EP | disclosed |
| EP-3171855-B1 | 11.BETA.-HYDROXYSTEROID-4-AZA-COMPOUNDS, COMPOSITIONS AND USES THEREOF | SPHAERA PHARMA PRIVATE LTD (IN) | 2020-08-26 | — | — | EP | disclosed |
| EP-3309166-A2 | 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION | Sphaera Pharma Pvt. Ltd. (IN) | 2018-04-18 | — | — | EP | disclosed |
| US-20170158730-A1 | HYDROXYSTEROID COMPOUNDS, THEIR INTERMEDIATES, PROCESS OF PREPARATION, COMPOSITION AND USES THEREOF | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-08 | — | — | US | disclosed |
| US-20170158730-A1 | HYDROXYSTEROID COMPOUNDS, THEIR INTERMEDIATES, PROCESS OF PREPARATION, COMPOSITION AND USES THEREOF | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-08 | — | — | US | disclosed |
| US-20150376225-A1 | NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION | EPIRIUM BIO INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150376225-A1 | NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION | EPIRIUM BIO INC. | 2015-12-31 | — | — | US | disclosed |
| WO-2014115167-A2 | NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION | SPHAERA PHARMA PVT. LTD. (IN) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158730-A1 | HYDROXYSTEROID COMPOUNDS, THEIR INTERMEDIATES, PROCESS OF PREPARATION, COMPOSITION AND USES THEREOF | HSD17B7, HSD11B1, HSD3B1 | HIF1A 1620/4885NR3C2 30/4885SMN1; SMN2 4666/4885 |
| US-20150376225-A1 | NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION | CYP27A1, CYP27B1, TFAM | HIF1A 446/4885NR3C2 285/4885SMN1; SMN2 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.